


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-1.27%
+3.92%
+1.72%
PFE
Pfizer
$25.51
Strengths

Earnings are forecast to grow

Trading below its fair value

Investors confidence is positive

Upgraded on attractively valued
Chart
$24.73 (+3.15%)
$25.14 (+1.47%)
$23.88 (+6.83%)
$25.13 (+1.51%)
PFE has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Investors losing confidence

PFE overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Earnings decline YoY

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive

Pays a reliable dividend
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
PFE Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
PFE Street Sentiment is bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayNVS
130.55
+2.60%
SNY
51.69
+2.03%
AZN
89.09
+1.84%
ABBV
225.17
+2.95%
LLY
988.62
+2.39%
What is PFE current stock price?
What are PFE stock strengths?
What risks are associated with PFE stock?
When is PFE next earnings report?
What is PFE market cap and volume?
What is PFE's current Stock IQ?
Should I buy PFE stock right now?
Is PFE a Strong Buy right now?
What does a 'Strong Buy' rating mean for PFE?
What does a 'Strong Sell' rating mean for PFE?
What factors influence PFE's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-1.27%
+3.92%
+1.72%
PFE
Pfizer
Current Price
$25.51
Stock Insights
Strengths

Earnings are forecast to grow

Trading below its fair value

Investors confidence is positive

Upgraded on attractively valued
Linked to PFE
NVS
130.55
+2.60%
SNY
51.69
+2.03%
AZN
89.09
+1.84%
ABBV
225.17
+2.95%
LLY
988.62
+2.39%

Chart
$24.73 (+3.15%)
$25.14 (+1.47%)
$23.88 (+6.83%)
$25.13 (+1.51%)
PFE Analysts Opinion
PFE Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Earnings decline YoY

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive

Pays a reliable dividend
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
PFE Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
PFE Street Sentiment is bullish and have positive views on the near-term outlook
PFE has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Investors losing confidence

Average key support and resistance price levels.
PFE Latest Analysis
Jim Cramer Says I Think Pfizers Very Smart to Buy Metsera. Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer offered insights on. Cramer discussed the companys acquisition of Metsera during the episode. He commented: Theres room for more than one winner in this race for GLP-1 weight loss supremacy but some of these winners are going to be bigger than others. This morning the [….]
Today
Why a Strong Quarter Wasnt Enough to Send Shares of Pfizer Soaring. Key PointsPfizers sales and profits came in better than expected for the third quarter.
Today
Pfizer Wins Obesity War Against NVO to Buy Metsera for Around $10B. Pfizer secures a $10B deal to buy Metsera ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.
Mon Nov 10, 2025
Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion.
Mon Nov 10, 2025
Pfizer Discusses Drug Pricing Deal Metsera Buyout Dispute on Q3 Call. Pfizer faces a fierce bidding war with Novo Nordisk over Metsera while securing a landmark United States drug pricing deal.
Fri Nov 7, 2025
Pfizer: The Storm Has Passed -- Tailwinds Ahead.
Thu Nov 6, 2025
Jim Cramer Highlights the Woes of Pfizer and the Drug Sector. Pfizer Inc. (NYSE:PFE) is one of the latest stocks on Jim Cramers radar. Cramer noted that the company could not perform as its entire industry is going through a tough time. He remarked: We also have a huge number of stocks that are sinking under their own weight high-quality companies real companies that are historically [….]
Thu Nov 6, 2025
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal. The Delaware Chancery Court denied ) request for a temporary restraining order to prevent ) from terminating the existing merger agreement in favor of a competing proposal from ).PfizerAntitrust regulators in the United States and abroad “.will not tolerate”. Novo Nordisk’.s attempt to “.potentially gain the ability ...
Thu Nov 6, 2025
Why Pfizers 7%-Yielding Dividend Just Became Safer -- and More Tempting. Key PointsPfizers Q3 earnings fell but the company still raised its full-year earnings guidance.
Thu Nov 6, 2025
Pfizer matches Novo bid for obesity biotech Metsera as takeover battle rages - FT.
Thu Nov 6, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.